Drugs / ISM5411
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06012578 | Nov 2023 → Sep 2024 | — | InSilico Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07265570 | Dec 2025 → Aug 2027 expected | ulcerative colitis | InSilico Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISM5411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012578 ↗ |
| Action | Inhibit | “prolyl hydroxylase (PHD) inhibitor” NCT07265570 ↗ |
| Modality | Small molecule | “gut-restricted small-molecule prolyl hydroxylase (PHD) inhibitor” NCT07265570 ↗ |
| Route | Oral | “single and multiple oral doses of ISM5411” NCT06012578 ↗ |